In a tentative ruling, plaintiffs’ claims that companies used deceptive marketing to increase unnecessary prescriptions was rejected<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Nov. 3, 2021 (HealthDay News) — A California judge has ruled against local governments that sued drug companies for billions of dollars to recover their costs of dealing with the opioid epidemic.<\/p>\n
In a tentative ruling issued Monday, Orange County Superior Court Judge Peter Wilson rejected the plaintiffs’ claims the companies used deceptive marketing to increase unnecessary prescriptions of opioid painkillers, the Associated Press<\/em> reported. “There is simply no evidence to show that the rise in prescriptions was not the result of the medically appropriate provision of pain medications to patients in need,” Wilson wrote in a ruling that entailed more than 40 pages.<\/p>\n The lawsuit by Los Angeles, Orange, and Santa Clara counties and the city of Oakland names Johnson & Johnson, AbbVie Inc.’s Allergan subsidiary, Endo International, Teva Pharmaceutical Industries. and other companies in its lawsuit. While disappointed by the ruling, the local governments said they planned to appeal to “ensure no opioid manufacturer can engage in reckless corporate practices that compromise public health in the state for their own profit,” the AP<\/em> reported.<\/p>\n The drug companies “successfully transformed the way doctors treat chronic pain, opening the floodgates of opioid prescribing and use,” the lawsuit contends. “This explosion in opioid prescriptions and use has padded Defendants’ profit margins at the expense of chronic pain patients.”<\/p>\n The plaintiffs projected that it could cost $50 billion to provide comprehensive opioid abatement programs in the four jurisdictions that filed the lawsuit, the AP<\/em> reported. The money would go for things like ongoing opioid abuse prevention and treatment programs in Los Angeles and Santa Clara counties.<\/p>\n The drug companies welcomed the judge’s ruling. In a statement, Johnson & Johnson said the decision showed it engaged in “appropriate and responsible” marketing of its opioid medications, the AP<\/em> reported.<\/p>\n